IRVINE, CA., April 6, 2023 /OrthoSpineNews/ – PUR Biologics, a subsidiary of HippoFi, Inc. (OTC Pink: ORHB), is proud to announce the launch of PURcore™, a novel moldable artificial with an interconnected micro-pore construction for spine surgical procedure. PURcore™ permits for the fast colonization of the affected person’s personal cells and progress elements which promotes bone regeneration and therapeutic.
As a subsidiary of HippoFi, PUR Biologics is dedicated to supporting hospitals and surgeon companions to offer the perfect care for his or her sufferers with a full line of biologic product choices. With the launch of PURcore™, PUR Biologics continues to reveal its authority and dedication to changing into the best-in-class spinal biologic firm.
“As a market chief in innovation, PUR Biologics is worked up to supply PURcore™ as one other cutting-edge product to assist affected person care. PURcore™ has outstanding dealing with properties and moldability, making it straightforward for spine surgeons to intraoperatively implant and hold this superior bioActive materials the place the specified therapeutic is to happen,” shared CJ Wiggins, Government Chairman & CEO of HippoFi.
The orthopedic and spine markets are displaying promising progress, with an estimated market alternative for bone progress merchandise of over $8B and a year-over-year progress fee of 6%.
“We’re thrilled to launch PURcore™ and supply a brand new possibility for surgeons to repeatedly improve their sufferers’ outcomes,” mentioned Ryan Fernan, Head of PUR Biologics. “The early suggestions now we have acquired from our prospects has been extraordinarily optimistic, and we’re assured that PURcore™ shall be an amazing addition to our market-leading portfolio of merchandise.”
For extra data on PURcore™ and PUR Biologics, please go to www.PURbiologics.com
About HippoFi, Inc.
HippoFi, Inc. delivers its cutting-edge healthcare improvements via an in depth gross sales channel community whereas implementing firstto-market options within the multibillion-dollar Biotech, Fintech, and Synthetic Intelligence (AI) markets. HippoFi contains three segments: Regenerative Therapeutics, Digital Funds, and AI, which make the most of the identical buyer channels to commercialize options, drive income, and enhance affected person outcomes.
PUR Biologics®, HippoFi’s Regenerative Therapeutic division, gives a portfolio of modern organic merchandise and proprietary applied sciences for bone progress in surgical Backbone procedures in addition to patented bioactive mobile matrix compositions and superior autologous cell therapies for regenerating cartilage in joints and spinal discs.
HippoFi, Inc. is publicly traded below the image: ORHB and is headquartered in Irvine, California. For extra data, please go to: www.hippofi.com and www.PURbiologics.com
Jason Brown Shareholder Communications